Recent advances in the prophylaxis and treatment of malaria

被引：12
作者：
Labbé A.-C. [1 ]
Loutfy M.R. [1 ]
Kain K.C. [1 ]
机构：
[1] Department of Medicine, Tropical Disease Unit, University Health Network, University of Toronto, 200 Elizabeth Street, EN G 224, Toronto, M5G 2C4, ON
来源：
Current Infectious Disease Reports | 2001年 / 3卷 / 1期
关键词：
Artesunate; Falciparum Malaria; Malaria; Mefloquine; Vivax Malaria;
D O I：
10.1007/s11908-001-0061-0
中图分类号：
学科分类号：
摘要：
Increases in international travel and escalating drug resistance are putting put a growing number of travelers at risk of contracting malaria. Resistance to chloroquine and proguanil and real and perceived intolerance to standard agents, such as mefloquine, has highlighted the need for new antimalarials to prevent and treat malaria. Promising new agents to prevent malaria include the combination of atovaquone and proguanil, primaquine, and a related 8-aminoquinoline, tafenoquine. These agents are active against the liver stage of the malaria parasite, and therefore can be discontinued shortly after the traveler leaves the malaria-endemic area; this offers a clear advantage, in terms of adherence to a treatment regimen. For treatment of multidrug-resistant Plasmodium falciparum malaria, the combination of artemisinin derivatives plus mefloquine, or atovaquone plus proguanil, are the most active drug regimens. © 2001, Current Science Inc.
引用
收藏
页码：68 / 76
页数：8
相关论文
共 67 条
  • [31] Walsh D.S., Eamsila C., Sasiprapha T., Et al., Randomized, double-blind, placebo controlled evaluation of monthly WR 238605 (TAFENOQUINE) for prophylaxis of Plasmodium falciparum and P. vivax in Royal Thai army soldiers. In Program and abstracts of the 48th annual meeting of the American Society of Tropical Medicine and Hygiene, In Am J Trop Med Hyg, 61, (1999)
  • [32] Shanks G.D., Possible options for malaria chemoprophylaxis on the horizon, J Travel Med, 6, pp. S31-S32, (1999)
  • [33] Andersen S.L., Ager A.L., McGreevy P., Et al., Efficacy of azithromycin as a causal prophylactic agent against murine malaria, Antimicrob Agents Chemother, 38, pp. 1862-1863, (1994)
  • [34] Anderson S.L., Berman J., Kuschner R., Et al., Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers, Ann Intern Med, 123, pp. 771-773, (1995)
  • [35] Andersen S.L., Oloo A.J., Gordon D.M., Et al., Successful doubleblinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya, Clin Infect Dis, 26, pp. 146-150, (1998)
  • [36] Taylor W.R., Richie T.L., Fryauff D.J., Et al., Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia, Clin Infect Dis, 28, pp. 74-81, (1999)
  • [37] Heppner D.G., Wongsrichanalai C., Walsh D.S., Et al., Azithromycin for the prophylaxis of malaria in Thailand, Am J Trop Med Hyg, 61, (1999)
  • [38] Walsh D.S., Looareesuwan S., Wilairatana P., Et al., Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand, J Infect Dis, 180, pp. 1282-1287, (1999)
  • [39] White N.J., The treatment of malaria, N Engl J Med, 335, pp. 800-806, (1996)
  • [40] Severe falciparum malaria, Trans R Soc Trop Med Hyg, 94, pp. S1-S90, (2000)
1234567